Incyte's Povorcitinib Shows Sustained Efficacy in Phase 3 HS Trial, Supports 2025/2026 Regulatory Submissions

Incyte Corporation (NASDAQ:INCY) is one of the best innovative stocks to buy now. On September 17, Incyte announced new 24-week interim data from its pivotal Phase 3 STOP-HS clinical trial program for povorcitinib/INCB54707, which is an oral small-molecule, highly-selective JAK1 inhibitor, in adult patients with moderate to severe hidradenitis suppurativa/HS.

The results support the company’s planned regulatory submissions for povorcitinib in HS, expected in Europe in 2025 and the US in early 2026. Both Phase 3 studies, STOP-HS1 and STOP-HS2, previously met their primary endpoint at the 12-week mark for both tested doses (45 mg and 75 mg) administered once daily, which was the achievement of HiSCR50.

The new 24-week data show continued clinically meaningful and statistically significant improvements, with nearly 60% of efficacy-evaluable patients across both povorcitinib treatment groups in both studies achieving HiSCR50. The overall safety profile was consistent with previous data, and both doses were well tolerated. HS is a chronic inflammatory condition estimated to affect more than 150,000 patients with moderate to severe HS in the US.

Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company that discovers, develops, and commercializes therapeutics in the US, Europe, Canada, and Japan.

While we acknowledge the potential of INCY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.